핵산 치료제 시장 규모, 점유율, 성장 분석 : 제품별, 적응증별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Nucleic Acid Therapeutics Market size was valued at USD 6.7 Billion in 2024 and is poised to grow from USD 7.61 Billion in 2025 to USD 21.12 Billion by 2033, growing at a CAGR of 13.6% during the forecast period (2026-2033).

The global nucleic acid therapeutics market is experiencing robust growth, driven by advancements in novel therapies and increased approvals. Nucleic acids, including DNA and RNA, play a crucial role in cellular information transfer and are pivotal in treating various chronic diseases such as cancer, diabetes, epilepsy, tuberculosis, and AIDS. The sector is gaining traction due to enhanced therapeutic efficacy and innovative drug development strategies within the pharmaceutical and biopharmaceutical industries. As healthcare organizations increasingly embrace these potent therapies, the demand for nucleic acid-based treatments continues to rise, positioning this market as a key player in the evolution of modern medicine and chronic disease management. This surge reflects a promising future for nucleic acid therapeutics.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Nucleic Acid Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Nucleic Acid Therapeutics Market Segments Analysis

Global Nucleic Acid Therapeutics Market is segmented by Product, Indication, End-user and region. Based on Product, the market is segmented into Anti-Sense Oligonucleotides (ASO), RNA Interference (RNAi) and RNA Aptamers. Based on Indication, the market is segmented into Autoimmune Disorders, Infectious Diseases, Genetic Disorders, Cancer and Others. Based on End-user, the market is segmented into Hospitals, Physicians' Offices and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Nucleic Acid Therapeutics Market

The Global Nucleic Acid Therapeutics market is significantly influenced by advancements in molecular technologies and the continuous exploration of omics, prompting substantial investment from various companies. This market is characterized by intense competition, where gaining market share is achieved through diverse business strategies, including acquisitions, partnerships, and collaborations that serve as critical revenue channels. For instance, strategic alliances between pharmaceutical firms focus on discovering, developing, and commercializing innovative RNA-based therapies aimed at addressing needs in vaccines, infectious diseases, and oncology. Such collaborative efforts are essential for fostering innovation and driving growth within this dynamic sector.

Restraints in the Global Nucleic Acid Therapeutics Market

One significant challenge facing the Global Nucleic Acid Therapeutics market is the effective delivery of these therapies to designated target cells. Achieving successful delivery is crucial, as it requires the therapeutic agents to accurately reach the intended tissue or cells while minimizing potential off-target effects. This complexity in the delivery process poses a major obstacle for researchers and developers aiming to optimize the efficacy and safety of nucleic acid-based treatments. The need for innovative delivery mechanisms and strategies continues to be a pressing concern within the industry, impacting the overall advancement and adoption of these therapeutic modalities.

Market Trends of the Global Nucleic Acid Therapeutics Market

The Global Nucleic Acid Therapeutics market is witnessing a robust upward trend, driven by heightened investments in healthcare services and research initiatives. This surge in funding is largely attributable to the rising prevalence of genetic disorders and chronic diseases, prompting urgent innovations within therapeutic landscapes. Advances in nucleic acid technologies, such as RNA-based therapies and gene editing, are gaining traction as they align with personalized medicine approaches aimed at targeting specific genetic conditions. As healthcare facilities evolve and expand their capabilities, the demand for nucleic acid therapeutics is anticipated to grow, leading to enhanced treatment options and improved patient outcomes globally.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Study Analysis

Global Nucleic Acid Therapeutics Market Size by Product & CAGR (2026-2033)

• Market Overview
• Anti-Sense Oligonucleotides (ASO)
• RNA Interference (RNAi)
• RNA Aptamers

Global Nucleic Acid Therapeutics Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Autoimmune Disorders
• Infectious Diseases
• Genetic Disorders
• Cancer
• Others

Global Nucleic Acid Therapeutics Market Size by End-user & CAGR (2026-2033)

• Market Overview
• Hospitals
• Physicians' Offices
• Others

Global Nucleic Acid Therapeutics Market Size & CAGR (2026-2033)

• North America (Product, Indication, End-user)
  • US
  • Canada
• Europe (Product, Indication, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Indication, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Indication, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Indication, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Wave Life Science Ltd. (Singapore)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Imugene (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aileron Therapeutics Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Protagonist Therapeutics Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Replicate Bioscience Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Copernicus Therapeutics Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Invio Pharmaceuticals Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Benitec Biopharma (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alnylam Pharmaceuticals (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Excision BioTherapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rhythm Pharmaceuticals Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Axcella Health Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations